News

News

Dec 20, 2021

Cytokinetics and JI XING Announce Expansion of Collaboration to Include Licensing of Omecamtiv Mecarbil in China; RTW to Add to Its Investment in Cytokineticsc

Dec 3, 2021

Ji Xing completes Phase 1 study of aficamten, a potential next-generation cardiac myosin inhibitor, for patients with hypertrophic cardiomyopathy (HCM)

Nov 19, 2021

JIXING Announces IND Approval for Phase 1 and Phase 3 Clinical Trials of Etripamil in Patients with Paroxysmal Supraventricular Tachycardia (PSVT) in China

Aug 6, 2021

Chinese startup with Merck vet at the helm acquires rights to Oyster Point’s eye disease nasal spray

Aug 5, 2021

Oyster Point Pharma Announces Exclusive License Agreement with JIXING Pharmaceuticals to Develop and Commercialize OC-01 and OC-02 in Greater China

Jul 13, 2021

RTW Investments-Backed JIXING Pharmaceuticals Appoints Joseph Romanelli Chief Executive Officer

May 17, 2021

Milestone Pharmaceuticals Announces Exclusive License Agreement with JIXING Pharmaceuticals to Develop and Commercialize Etripamil for PSVT in Greater China

Jul 14, 2020

RTW Investments, LP, JIXING Pharmaceuticals and Cytokinetics Enter Intro Strategic Financing Collaboration to Support the Development of CK-274 and Enter China

View All News